<DOC>
	<DOCNO>NCT01500317</DOCNO>
	<brief_summary>Tapentadol FDA approve treatment moderate severe acute pain . Due dual mechanism action opioid agonist norepinephrine reuptake inhibitor , potential label use chronic pain . Tapentadol new molecular entity structurally similar tramadol . Tapentadol centrally-acting analgesic dual mode action agonist mu-opioid receptor norepinephrine reuptake inhibitor . These two action synergistic pain relief . While action reflect aspect tramadol morphine , ability control pain order hydrocodone oxycodone . Its dual mode action provide analgesia similar level potent narcotic analgesic hydrocodone , oxycodone , meperidine tolerable side effect profile . Clinical study show tapentadol effectively relieve moderate severe pain various pain care setting . In addition , report associate significantly few treatment discontinuation due significantly low incidence gastrointestinal-related adverse event compare equivalent dos oxycodone . The combination reduce treatment discontinuation rate tapentadol efficacy relief moderate severe nociceptive neuropathic pain may offer improvement pain therapy increase patient compliance treatment regimen .</brief_summary>
	<brief_title>Comparison Effects Tapentadol Oxycodone Gastrointestinal Colonic Transit Humans</brief_title>
	<detailed_description>Single center , parallel group , randomize control trial tapentadol , oxycodone placebo effect gastrointestinal colonic transit healthy human volunteer</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Healthy volunteer Inclusion criterion 1 . Males nonpregnant , nonbreastfeeding female 2 . 1865 year old Exclusion criterion 1 . Use muopioid agent last 3 month 2 . Structural metabolic diseases/conditions affect gastrointestinal system , functional gastrointestinal disorder . For screen shorten screen version Bowel Disease Questionnaire ( Appendix ) use exclude subject dyspepsia , irritable bowel syndrome significant gastrointestinal symptom . Of 19 question , participant three less positive eligible participate . 3 . Unable withdraw medication 48 hour prior study : Alter GI transit include laxative , magnesium aluminumcontaining antacid , prokinetics , erythromycin , narcotic , anticholinergic , tricyclic antidepressant , selective serotonin reuptake inhibitor ( SSRIs ) new antidepressant . Analgesic drug include opiate , nonsteroidal antiinflammatory drug ( NSAIDs ) , COX 2 inhibitor SSRI NOTE : Low stable dos thyroid replacement , estrogen replacement , low dose aspirin cardioprotection birth control pills depot injection permissible . 4 . Female subject pregnant breast feeding . 5 . Clinical evidence ( include physical exam , ECG , hemoglobin level review medical history ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study . 6 . Subjects consider investigator alcoholic remission know substance abuser . 7 . Subjects participate another clinical study within past 30 day 8 . History porphyria , renal ( creatinine &gt; 1.5mg/dL ) significant liver impairment ( transaminase , alkaline phosphatase gammaglutamyl transpeptidase ( GGT ) &gt; 2 time upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>tapentadol</keyword>
	<keyword>oxycodone</keyword>
	<keyword>mu-opiate</keyword>
	<keyword>stomach</keyword>
	<keyword>small intestine</keyword>
	<keyword>colon</keyword>
	<keyword>motility</keyword>
	<keyword>nausea</keyword>
	<keyword>constipation</keyword>
</DOC>